Established in: 1935
Managing Director: Achin Gupta
Cipla Limited is an Indian multinational pharmaceutical company established in 1935 and headquartered in Mumbai, Maharashtra. The company focuses on developing medicines to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical illnesses.
Cipla has around 47 manufacturing facilities across the world, sells its products in over 86 countries, and is the third largest drug producer in India. The company also sells active pharmaceutical ingredients to other manufacturers, along with personal care products, including anti-depressant escitalopram oxalate, lamivudine, and fluticasone propionate. Cipla is the largest manufacturer of antiretroviral drugs in the world.
The company launched their IPO and went public in 1979, and is now listed on both Indian stock exchanges, BSE and NSE. Cipla Limited is a constituent of the BSE Sensex and the NSE CNX Nifty. The company’s Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.
History of Cipla Limited
Khawaj Abdul Hamied, the founder of Cipla, met with Mahatma Gandhi in the early 1920s and decided to contribute to the Swadeshi movement by pursuing a Doctorate in chemistry. In 1935, Khawaj Abudl Hamied founded Cipla as the Chemical, Industrial and Pharmaceutical Laboratories in Mumbai, Maharashtra.
Business Segments of Cipla Limited
Cipla Limited has two primary business segments: Pharmaceutical and New Ventures.
-
Pharmaceutical Segment
This segment is the core revenue driver for Cipla and oversees its generic and active pharmaceutical ingredients operations. It manufactures prescription drugs, generic medications and active pharmaceutical ingredients for its own use and for other manufacturers as well.
-
New Ventures Segment
This division focuses on the long-term sustainability of the company by entering into new and specialised medical sectors. The subsidiary company, Cipla Health, is producing fast-moving consumer health and wellness products. The company is now focusing on developing recombinant proteins and advanced biologics to target chronic and severe diseases.
Cipla Limited is pioneering drug-device combinations, proprietary formulations and targeted regenerative therapies for critical care and respiratory delivery systems.
Subsidiaries of Cipla Limited
Cipla Limited has a network of Indian and international subsidiaries. The following are the subsidiaries of Cipla Limited.
- Cipla Health Limited
- Cipla Pharmaceuticals Limited
- Cipla Digital Health Limited
- Goldencross Pharma Limited
- Jay Precision Pharmaceuticals Private Limited
- Medispray Laboratories Private Limited
- Meditab Specialities Limited
- Sitec Labs Limited
- Cipla BioTec Limited
- Cipla USA Incorporation
- Cipla Medpro South Africa (Pty) Limited
- Cipla Quality Chemical Industries Limited (Uganda)
- Cipla Europe NV
- Cipla Gulf FZ-LLC / Cipla Middle East Pharmaceuticals FZ-LLC (UAE)
Awards and Recognition Received by Cipla Limited
The following are the awards and recognitions received by Cipla Limited over the years.
- 1980: Cipla was awarded the Chemexcil Award for Excellence in exports.
- 2006: Cipla was awarded the Dun & Bradstreet American Express Corporate Awards.
- 2007: Cipla was included in the Forbes 200 'Best under a billion' list of best small Asian companies.
- 2012: Cipla received the Thomson Reuters India Innovation Award.
- 2015: Cipla stood third in India's Most Reputed Brands in the Pharmaceutical sector list in a study conducted by BlueBytes.
- 2025: Cipla received the Economic Times Healthcare Award for Excellence in Health and Wellness (Product & Technology).
- 2026: Cipla was honoured with the Outstanding Pharma Project Culture (Organisation) award.
Cipla Financial Highlights
- Revenue: Cipla reported revenue of ₹29,044.60 crore in FY26 vs ₹28,409.49 crore in FY25. It showed an increase of 2.24% on a yearly basis.
- Operating Profit: Cipla reported an operating profit of ₹5,223.63 crore in FY26 vs ₹6,820.81 crore in FY25. It showed a decrease of 23.42% on a year-on-year basis.
- Net Profit: Cipla reported a net profit of ₹3,869.79 crore in FY26 vs ₹5,291.05 crore in FY25. It showed a decrease of 26.86% on a yearly basis.
Cipla Quarterly Result Highlights
- Cipla reported revenue of ₹7,330.18 crore in Jun 2026, compared with ₹6,689.36 crore in Mar 2026, representing an increase of 9.58% on a quarter-on-quarter (QoQ) basis.
- Cipla reported an operating profit of ₹1,081.93 crore in Jun 2026, compared with ₹707.06 crore in Mar 2026, representing an increase of 53.02% on a quarter-on-quarter (QoQ) basis.
- Cipla reported a profit of ₹787.10 crore in Jun 2026, compared with ₹550.11 crore in Mar 2026, reflecting an increase of 43.08% on a QoQ basis.
- The earnings per share (EPS) of Cipla stood at ₹48.03 during Jun 2026.
Data Source: BSE, Company announcements
Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.
